Loretta L Nielsen

Summary

Affiliation: Amylin Pharmaceuticals
Country: USA

Publications

  1. ncbi request reprint Pharmacology of exenatide (synthetic exendin-4): a potential therapeutic for improved glycemic control of type 2 diabetes
    Loretta L Nielsen
    Amylin Pharmaceuticals Inc, 9360 Town Centre Dr Ste 110, San Diego, CA 92121, USA
    Regul Pept 117:77-88. 2004
  2. ncbi request reprint Incretin mimetics and DPP-IV inhibitors for the treatment of type 2 diabetes
    Loretta L Nielsen
    Amylin Pharmaceuticals, 9360 Towne Centre Drive, Suite 110, San Diego, CA 92121, USA
    Drug Discov Today 10:703-10. 2005
  3. ncbi request reprint Exenatide (exendin-4) improves insulin sensitivity and {beta}-cell mass in insulin-resistant obese fa/fa Zucker rats independent of glycemia and body weight
    Bronislava R Gedulin
    Amylin Pharmaceuticals, Inc, 9360 Towne Centre Drive, Suite 110, San Diego, California 92121, USA
    Endocrinology 146:2069-76. 2005
  4. doi request reprint Pharmacokinetics and pharmacodynamics of exenatide following alternate routes of administration
    Bronislava R Gedulin
    Amylin Pharmaceuticals, Inc 9360 Towne Centre Dr, Ste 110, San Diego, CA 92121, United States
    Int J Pharm 356:231-8. 2008
  5. ncbi request reprint Pharmacokinetics, pharmacodynamics, and safety of exenatide in patients with type 2 diabetes mellitus
    Orville G Kolterman
    Amylin Pharmaceuticals Inc, 9360 Towne Centre Drive, Suite 110, San Diego, CA 92121, USA
    Am J Health Syst Pharm 62:173-81. 2005
  6. ncbi request reprint Patient characteristics, drug adherence patterns, and hypoglycemia costs for patients with type 2 diabetes mellitus newly initiated on exenatide or insulin glargine
    Rosalind Fabunmi
    Amylin Pharmaceuticals Inc, San Diego, CA, USA
    Curr Med Res Opin 25:777-86. 2009
  7. ncbi request reprint Investigation of exenatide elimination and its in vivo and in vitro degradation
    Kathrin Copley
    Amylin Pharmaceuticals, Inc 9360 Towne Centre Dr, Ste 110, San Diego, CA 92121, USA
    Curr Drug Metab 7:367-74. 2006
  8. ncbi request reprint Pharmacology of exenatide (synthetic exendin-4) for the treatment of type 2 diabetes
    Loretta L Nielsen
    Amylin Pharmaceuticals Inc, 9373 Towne Centre Drive, San Diego, CA 92121, USA
    Curr Opin Investig Drugs 4:401-5. 2003
  9. ncbi request reprint Incretin mimetics and DPP-IV inhibitors: new paradigms for the treatment of type 2 diabetes
    Deborah Hinnen
    Mid America Diabetes Associates, Wichita, KS 67211, USA
    J Am Board Fam Med 19:612-20. 2006
  10. ncbi request reprint Metabolic effects of two years of exenatide treatment on diabetes, obesity, and hepatic biomarkers in patients with type 2 diabetes: an interim analysis of data from the open-label, uncontrolled extension of three double-blind, placebo-controlled trials
    John B Buse
    Division of Endocrinology, Department of Medicine, University of North Carolina School of Medicine, Chapel Hill, North Carolina, USA
    Clin Ther 29:139-53. 2007

Collaborators

Detail Information

Publications12

  1. ncbi request reprint Pharmacology of exenatide (synthetic exendin-4): a potential therapeutic for improved glycemic control of type 2 diabetes
    Loretta L Nielsen
    Amylin Pharmaceuticals Inc, 9360 Town Centre Dr Ste 110, San Diego, CA 92121, USA
    Regul Pept 117:77-88. 2004
    ....
  2. ncbi request reprint Incretin mimetics and DPP-IV inhibitors for the treatment of type 2 diabetes
    Loretta L Nielsen
    Amylin Pharmaceuticals, 9360 Towne Centre Drive, Suite 110, San Diego, CA 92121, USA
    Drug Discov Today 10:703-10. 2005
    ..e. appetite suppression). Based on preliminary clinical data, incretin mimetics and DPP-IV inhibitors show potential for treating type 2 diabetes...
  3. ncbi request reprint Exenatide (exendin-4) improves insulin sensitivity and {beta}-cell mass in insulin-resistant obese fa/fa Zucker rats independent of glycemia and body weight
    Bronislava R Gedulin
    Amylin Pharmaceuticals, Inc, 9360 Towne Centre Drive, Suite 110, San Diego, California 92121, USA
    Endocrinology 146:2069-76. 2005
    ....
  4. doi request reprint Pharmacokinetics and pharmacodynamics of exenatide following alternate routes of administration
    Bronislava R Gedulin
    Amylin Pharmaceuticals, Inc 9360 Towne Centre Dr, Ste 110, San Diego, CA 92121, United States
    Int J Pharm 356:231-8. 2008
    ..Despite little optimization of the delivery formulation, exenatide bioavailability compared favorable to that of several commercially available bioactive peptides...
  5. ncbi request reprint Pharmacokinetics, pharmacodynamics, and safety of exenatide in patients with type 2 diabetes mellitus
    Orville G Kolterman
    Amylin Pharmaceuticals Inc, 9360 Towne Centre Drive, Suite 110, San Diego, CA 92121, USA
    Am J Health Syst Pharm 62:173-81. 2005
    ..The pharmacology and tolerability of exenatide in patients with type 2 diabetes mellitus were studied...
  6. ncbi request reprint Patient characteristics, drug adherence patterns, and hypoglycemia costs for patients with type 2 diabetes mellitus newly initiated on exenatide or insulin glargine
    Rosalind Fabunmi
    Amylin Pharmaceuticals Inc, San Diego, CA, USA
    Curr Med Res Opin 25:777-86. 2009
    ..Examine real-world effectiveness and hypoglycemia cost burden in patients with type 2 diabetes newly initiated on exenatide or insulin glargine...
  7. ncbi request reprint Investigation of exenatide elimination and its in vivo and in vitro degradation
    Kathrin Copley
    Amylin Pharmaceuticals, Inc 9360 Towne Centre Dr, Ste 110, San Diego, CA 92121, USA
    Curr Drug Metab 7:367-74. 2006
    ..Exenatide (15-39) and (16-39) had moderate-to-weak antagonist activity compared with the known antagonist, exenatide (9-39). In conclusion, the kidney appears to be the primary route of elimination and degradation of exenatide...
  8. ncbi request reprint Pharmacology of exenatide (synthetic exendin-4) for the treatment of type 2 diabetes
    Loretta L Nielsen
    Amylin Pharmaceuticals Inc, 9373 Towne Centre Drive, San Diego, CA 92121, USA
    Curr Opin Investig Drugs 4:401-5. 2003
    ..Ongoing studies suggest exenatide improves glycemic control through a combination of mechanisms discussed in this review...
  9. ncbi request reprint Incretin mimetics and DPP-IV inhibitors: new paradigms for the treatment of type 2 diabetes
    Deborah Hinnen
    Mid America Diabetes Associates, Wichita, KS 67211, USA
    J Am Board Fam Med 19:612-20. 2006
    ..The use of these agents may provide an opportunity to bring about new improvements in diabetes care...
  10. ncbi request reprint Metabolic effects of two years of exenatide treatment on diabetes, obesity, and hepatic biomarkers in patients with type 2 diabetes: an interim analysis of data from the open-label, uncontrolled extension of three double-blind, placebo-controlled trials
    John B Buse
    Division of Endocrinology, Department of Medicine, University of North Carolina School of Medicine, Chapel Hill, North Carolina, USA
    Clin Ther 29:139-53. 2007
    ..Some patients were followed up in open-label extensions to provide 'real-world' exenatide clinical experience...
  11. ncbi request reprint Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years
    David C Klonoff
    Diabetes Research Institute, Mills Peninsula Health Services, San Mateo, CA, USA
    Curr Med Res Opin 24:275-86. 2008
    ..The objective of this study was to evaluate the effects of > or = 3 years exenatide therapy on glycemic control, body weight, cardiometabolic markers, and safety...
  12. ncbi request reprint Exenatide augments first- and second-phase insulin secretion in response to intravenous glucose in subjects with type 2 diabetes
    Frauke Fehse
    Diabeteszentrum Bad Lauterberg, Kirchberg 21, D 37431 Bad Lauterberg im Harz, Germany
    J Clin Endocrinol Metab 90:5991-7. 2005
    ..The incretin mimetic exenatide has glucoregulatory activities in DM2, including glucose-dependent enhancement of insulin secretion...